UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL					
OMB Number:	3235-0287				
stimated average burden					
ours per response.	0.5				

longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type	e Responses)														
1. Name and Address of Reporting Person * SCHEDER-BIESCHIN MAX				2. Issuer Name and Ticker or Trading Symbol EKSO BIONICS HOLDINGS, INC. [EKSO]						5.	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
(Last) (First) (Middle) C/O EKSO BIONICS HOLDINGS, INC., 1414 HARBOUR WAY SOUTH, SUITE 1201			NC., 1414	3. Date of Earliest Transaction (Month/Day/Year) 06/11/2015							X Officer (give title below) Other (specify below) Chief Financial Officer					
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)								6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person				
RICHMON (City)	ND, CA 94	(State)	(Zip)	Table I No. Budanta Comité							Acquire	ired, Disposed of, or Beneficially Owned				
1.00	•.			24 D												27.4
1.Title of Sec (Instr. 3)	curity		2. Transaction Date (Month/Day/Year)		n D	ate, if Co			4. Securit (A) or Di (Instr. 3,	sposed o	of (D) Or Tr	Amount of So wned Followi ransaction(s) nstr. 3 and 4)		(F I c	Ownership o orm: B Oirect (D) C r Indirect (I	eneficial wnership
Reminder: R	eport on a se	eparate line for each	class of securities l	oeneficial	ly o	wned dire	ectly o	Perso	ns who ned in t	his forr	m are no	collection of required to the contract to the	o respond	unless the	SEC 14	74 (9-02)
			Table II - I					ired, Disp				Owned			1	
Derivative Conversion Date		3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	if Transaction Code (Instr. 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s	Ownership Form of Derivative Security: Direct (D) or Indirect		
				Code	v	(A)	(D)	Date Exercisal		ration	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)	
Employee Stock Option (right to buy)	\$ 1.37	06/11/2015		A		313,000)	(1)	06/1	1/2025	Comme Stock	1313 000	\$ 0	313,000	D	
Report	ing O	wners				Doloti										

D (1 0 N / 11)	Relationships							
Reporting Owner Name / Address		10% Owner	Officer	Other				
SCHEDER-BIESCHIN MAX C/O EKSO BIONICS HOLDINGS, INC. 1414 HARBOUR WAY SOUTH, SUITE 1201 RICHMOND, CA 94804			Chief Financial Officer					

Signatures

Michelle L. Basil, as Attorney-in-Fact	06/15/2015
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The option becomes exercisable as to 25% of the total number of shares on June 11, 2016, and thereafter vests in equal monthly installments for 36 months.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.